AGT 182

Drug Profile

AGT 182

Alternative Names: AGT182; IgG iduronate 2 sulfatase fusion protein; Insulin receptor MoAb-IDS fusion protein; Recombinant human insulin receptor monoclonal antibody-fused iduronate 2 sulfatase; SHP 631

Latest Information Update: 14 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ArmaGen Technologies
  • Class Iduronate sulfatases; Immunoglobulin fusion proteins; Monoclonal antibodies
  • Mechanism of Action Iduronate sulfatase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis II
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Mucopolysaccharidosis II

Most Recent Events

  • 14 Aug 2017 AGT 182 is still in phase-I/II clinical trials in Mucopolysaccharidosis II in USA (IV) (NCT02262338) (ArmaGen pipeline, August 2017)
  • 14 Jul 2016 Efficacy and adverse events data from a phase I/IIa trial in Mucopolysaccharidosis II released by ArmaGen
  • 01 Mar 2015 Phase-I/II clinical trials in Mucopolysaccharidosis II in USA (IV) (NCT02262338)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top